BeiGene (BGNE) sees Significant Insider Sales

Wednesday, November 15, 2017 10:15 PM ET

BeiGene (BGNE) sees Significant Insider Sales

There was substantial level of selling of BeiGene shares today, as revealed in filings with the SEC. Two insiders — John Oyler, 10% Owner, Director and Officer, and Amy C Peterson, Officer — disposed of 154,558 shares in the company having a market value of approximately $12,451,121. These are the first insider buy/sell trades in the past 90 days. Adding the most recent activity to this 90-day history indicates insider trades have averaged 77,279 shares per transaction.

Over the last 90 days, the number of insider buy/sell trades at BeiGene is greater than its 271-company peer group average. The Bio Therapeutic Drugs peer group saw 329 buy/sell trades during this period for an average of 1.2 transactions per company. However, the number of shares traded per transaction by BeiGene insiders is lower than its peers. Within the peer group there were 32,142,994 shares purchased and 20,985,363 shares sold with company insiders purchasing 55,236 shares on average over this time period.

Insider buying and selling activity that is significant has been determined by eliminating all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers in evaluating and writing this story.

Today’s Insider Activity
* John Oyler, 10% Owner, Director and Officer, sold 150,957 shares
* Amy C Peterson, Officer, sold 3,601 shares

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at Copyright 2017 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.